肾癌组织中线粒体融合蛋白2基因的表达及临床意义  

Expression and clinical significance of Mitofusion 2 mRNA in renal cell carcinoma

作　　者：甘妙平[1] 李剑峰[1] 郑燕深 

机构地区：[1]惠州市中心人民医院泌尿外科,广东惠州516001

出　　处：《现代泌尿外科杂志》2016年第9期673-675,共3页Journal of Modern Urology

摘　　要：目的检测肾细胞癌线粒体融合蛋白-2(Mfn2)基因表达的变化,探讨其相关的临床意义。方法选取我院2014年2月至2016年1月收治的肾细胞癌患者74例,另取同期我院肾小球活检排除肾癌者30例作为对照组。Mfn2基因表达量使用荧光定量PCR检测。结果 Mfn2在肾癌组织中表达量为0.182±0.031,显著低于对照肾组织的0.325±0.047(P<0.01)。肾癌组织中男女性别、不同年龄以及肿瘤病理类型之间Mfn2表达量无显著性差异(P>0.05)。Ⅲ、Ⅳ临床分期患者Mfn2表达量为0.146±0.029,显著低于Ⅰ、Ⅱ临床分期患者的0.212±0.038(P<0.05)。肿瘤有淋巴结转移患者Mfn2表达量为0.151±0.024,显著低于无淋巴结转移患者的0.228±0.042(P<0.05)。肿瘤中、低分化患者Mfn2表达量为0.154±0.028,显著低于高分化患者的0.231±0.051(P<0.05)。结论 Mfn2基因在肾癌组织中低表达,Mfn2基因表达量与肾癌的临床分期、有无淋巴结转移以及肿瘤分化程度密切相关。Objective To detect mitofusion 2 （Mfn2） mRNA expression in renal cell carcinoma （RCC） and to explore its clinical significance. Methods A total of 74 RCC cases and another 30 non-RCC controls were enrolled in this study. Realtime PCR was used to detect Mfn2 mRNA expression. Results Mfn2 mRNA expression was 0. 182±0. 031 vs. 0. 325±0. 047 in RCC cases and controls （P〈0.01）. There were no statistical differences in Mfn2 mRNA expression between RCC patients of different gender, age, and pathological type （P〉0.05）. Mfn2 mRNAexpression was 0. 146±0. 029 in Ⅲ and Ⅳ stage and 0.212 ± 0. 038 in Ⅰ and Ⅱ stage （P〈0.05）. Mfn2 mRNA expression was 0.151± 0. 024 vs. 0.. 228 ± 0. 042 in lymph node metas- tasis group and non-lymph node metastasis group （P〈0.05）. Mfn2 mRNA expression was 0. 154±0. 028 vs. 0. 231±0. 051 in median and low differentiation group, and well differentiation group （P〈0.05）. ConclusionLow expression of Mfn2 mR- NA was detected in RCC, which was closely related to clinical stage, lymph node metastasis, and tumor differentiation.

关 键 词：肾癌 线粒体融合蛋白-2基因 荧光定量PCR 

分 类 号：R737.11[医药卫生—肿瘤]